full Prescribing Information and Medication Guide, including With ACTEMRA IV infusions, you may be able to treat your moderate to severe RA with or without. Full Prescribing Information ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have. Actemra® (tocilizumab) pre-filled syringe for subcutaneous (SC) injection. Patients Consumer Medicine Information (CMI). Healthcare Professionals.
|Published (Last):||1 April 2013|
|PDF File Size:||16.19 Mb|
|ePub File Size:||10.2 Mb|
|Price:||Free* [*Free Regsitration Required]|
informmation Your healthcare provider should test you for hepatitis B before starting treatment. The most common events occurring during infusion were headache, nausea and hypotension, and occurring within 24 hours of infusion were dizziness and hypotension.
Rheumatoid Arthritis Treatment | ACTEMRA® (tocilizumab)
All Interactions Sort By: Do not dilute vials until after successfully obtaining intravenous access. The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Serious allergic reactions, including death, can happen with ACTEMRA infusions or injections, even if they did not occur with an earlier infusion or injection.
Adding plans allows you to compare formulary status to other drugs in the same class. These parts include the Ohio and Mississippi River Valleys and the Southwest Lrescribing B or have had hepatitis B Be sure to contact your healthcare provider or nurse if you see any signs of these side effects. The link you have pprescribing will take you away from this site to one that is not owned or controlled by Prescribign, Inc.
Peak plasma time in RA patients: ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Withdraw a volume of 0.
Demyelinating Disorders—use with caution in patients with preexisting or recent onset demyelinating disorders. You should not do both. Two additional patients developed MAS during the long-term extension. Most Popular Articles According to Rheumatologists.
Patients with invasive fungal infections may present with disseminated, rather than localized, disease. To view formulary information first create a list of plans. Infusion Reactions In PJIA patients, infusion-related reactions are defined as all events prescribung during or within 24 hours of an infusion.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Laboratory Parameters Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests.
Tell your healthcare provider right away if you see any signs of these symptoms:. Tocilizumab has inrormation been studied in combination with biological DMARDs eg, TNF antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies, selective costimulation modulators and its use should be avoided in combination with these agents because of increased immunosuppression and risk of infection.
This website also contains material copyrighted by 3rd parties. Infection signs, with or without a fever, include sweating or chills; shortness of breath; warm, red or painful skin or sores on your body; feeling very tired; muscle aches; blood in phlegm; diarrhea or stomach niformation cough; weight loss; burning when you urinate or urinating more often than normal Any of the following conditions that may give you a actemraa chance of getting infections.
Your healthcare provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start receiving ACTEMRA, and then every 6 months after that You should not receive ACTEMRA if your neutrophil and platelet counts are too low or your liver function test levels are too high. Recommended iinformation Procedures. Your email has been sent! ACTEMRA is indicated prescgibing the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
Impact of treatment with tocilizumab on demyelinating disorders is unknown, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in RA clinical studies; monitor for signs and symptoms potentially indicative of demyelinating disorders. Controlled studies in pregnant women show no evidence of fetal risk. Print without Office Info. Non-Medicare Plans Medicare Plans. Undiluted vials and prefilled SC syringes: This drug is available at a middle level co-pay.